Clinical trial
Phase I (PH I) Mad Refractory Solid Tumor Study
NCT00099606 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00099606 |
|---|---|
| Title | Phase I (PH I) Mad Refractory Solid Tumor Study |
| Official title | A Phase I Dose-Escalation Study of BMS-354825 in Patients With Refractory Solid Tumors |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | Dasatinib |
| Enrollment | 60 |
| Start date | Jul 1, 2004 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Dec 20, 2004 |
| Last update posted | Apr 19, 2011 |
| Countries | United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: